Background {#Sec1}
==========

Heart failure is a growing health challenge and among the major causes of death in developing countries along with the progression of the aging society, particularly in women \[[@CR1], [@CR2]\].

It has been generally accepted that female gender is associated with better survival (either crude and/or age-adjusted) compared with male gender in the broad spectrum of HF especially of a non-ischemic etiology, while other registries demonstrated no differences in the prognoses of male and female patients \[[@CR3]\].

In the few studies from low-income countries, the gender distribution appears equal but age is much lower than in developed countries \[[@CR4]\]. Etiologies have previously varied but recent studies suggest that HF in these countries increasingly shifts towards the pattern seen in developed countries with regard to risk factors, etiology, and comorbidity \[[@CR5]\].

It continues to be mandatory to clarify, however, whether gender differences exist among Egyptian acute HF patients. Thus, in the present study, we addressed clinical characteristics and in-hospital management/outcomes of women using acute HF registry database (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Gender difference of HF clinical characteristics

Methods {#Sec2}
=======

Baseline patient data {#Sec3}
---------------------

The present study is a single-center, prospective observational study. We enrolled 1006 consecutive patients \> 18 years old with emergency admission to the CCU in university hospitals, a representative to tertiary academic center in Egypt between July 2015 and July 2016. Patients included in the study were those hospitalized due to worsening HF or new onset as the leading cause of admission. Patients in stages C--D HF were included in focused analysis \[[@CR6]\]. The diagnosis of HF was based on the Framingham criteria for clinical HF \[[@CR6]\]. The entry data were gathered by using an electronic data capture system; it included demographic data, etiology of HF, medical history, patient presentation, functional status, laboratory findings, and medications. The study data were collected on admission and throughout the hospital course by the expert registry team.

Definitions of the all variables registered from the patients, outcome parameters as well as the diagnosis of disease entity like cardiogenic shock, ACS infective endocarditis, and cardiomyopathies, were carried out following the American College of Cardiology (ACC) clinical data standards \[[@CR7]\]. Valvular heart disease was defined as moderate to severe aortic and/or mitral valve disease with or without a previous history of valvular surgery, while hypertensive heart disease was defined as the presence of concentric left ventricular hypertrophy (mean thickness of the ventricular septum and LV posterior wall ≥ 12 mm) in patients with a history of or receive treatment for hypertension.

Clinical characteristics, risk factors, and previous history were determined. All included patients are symptomatic functional class (NYHA) II--IV. In the emergency department, the handling physician diagnosed HF within 30 min of admission (depending on the described criteria) by filling out a patient standard report form. HF was defined as new-onset HF or acute decompensation of chronic HF with symptoms that were sufficient to warrant hospitalization \[[@CR7]\].

The Charlson comorbidity index (CCI) \[[@CR7]\] is a method that predicts mortality by classifying or weighting comorbidities like stroke, renal disease, liver disease, and cancer. It is an intensive care index utilized by health researchers to assess disease burden and considered to be an applicable prognostic indicator for mortality.

Outcomes {#Sec4}
--------

The status of registered patients was surveyed during hospitalization; the following information was obtained: duration of hospital stay, death, and patient destination after discharge (home or ward).

### Statistical analysis {#Sec5}

All demographic, clinical characteristics, medications, and intervention were compared using *χ*^2^ test for categorical variables and unpaired *t* test for continuous variables. The relationship between gender and hospital outcomes was assessed using logistic regression analysis. Cox proportional hazard modeling was employed to all-cause mortality during hospital course. Recorded data were analyzed using the Statistical Package for Social Sciences, version 20.0 (SPSS Inc., Chicago, Illinois, USA). Quantitative data were expressed as mean ± SD. Qualitative data were expressed as frequency and percentage, and *P* value less than 0.05 was considered significant. Adjusted outcomes were presented as hazard ratio (HR) with 95% confidence interval (CI).

Results {#Sec6}
=======

Baseline characteristics of women and men with HF, women with and without HF, and comparison of women with HFrEF and HFpEF are listed in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, and [3](#Tab3){ref-type="table"}. Among the 1006 patients admitted to CCU in 1 year, 345(34.2%) patients were females and 118 (34.2%) had evidence of HF, whereas 661 (65.7%) were males; 178 (26.9%) of them had HF. Regarding the HF type, in women, 73 (61.9%) had HFrEF versus 113 (63.5%) in men, *P* = 0.345, while 45 (38.1%) had HFpEF versus 65 (36.5%) in men, P = 0.378. Table 1Characteristics of HF according to genderMale, *n* = 178Female, *n* = 118*P* valueHFrEF113 (63.5%)73 (61.9%)0.579Age59.9 ± 965.3 ± 110.0001BMI29.84 ± 3.231.63 ± 40.01Obesity81 (54.5%)80 (67.8%)0.000DM74 (41.6%)45(38.1%)0.628HTN109 (61.2%)67(56.8%)0.470Dyslipidemia59 (33.1%)47(39.8%)0.266Smoking120 (67%)2 (1.7%)0.000Previous MI52 (29.6%)19 (16.1%)0.019Previous PCI34 (19.1%)12 (10.2%)0.043Prior CABG18 (10.1%)8 (6.78%)0.226Valve surgery8 (4.5%)6 (5.1%)0.339Addiction13 (7.3%)0 (0%)0.001STEMI22 (12.4%)16 (14%)0.329UA/NSTEMI16 (9%)21 (8.5%)0.878Cardiogenic shock39 (22%)25 (21.2%)0.351CHB3 (1.7%)1 (0.8%)0.296AF/Flutter16 (8.9%)25 (21.2%)0.041IE1 (0.6%)1 (0.8%)0.916PE1 (0.6%)3 (2.5%)0.148Aortic dissection1 (0.6%)3 (2.5%)0.148Cardiomyopathies18 (10.1%)23 (19.5%)0.011Chest pain (CP)35 (19.7%)25 (21.2%)0.199Orthopnea118 (66%)80 (67.8%)0.195PND40 (22.5%)16 (13.6%)0.040Palpitations18 (10.1%)14 (11.9%)0.191Syncope10 (5.62%)1 (0.85%)0.024Cough55 (30.9%)38 (32.2%)0.704Edema63 (35.4%)38 (32.2%)0.847Pacemaker5 (2.8%)2 (1.7%)0.320ICD0 (0%)1 (0.85%)0.163Killip class I33 (18.5%)11 (5.9%)0.023 II8 (4.5%)6 (5.1%)0.211 III32 (18%)27(22.8%)0.119 IV102 (57%)71 (60.2%)0.176Pricardiocentesis3 (1.7%)1 (0.85%)0.541Thazides22 (12.4%)8 (6.8%)0.119Loop diuretics109 (61%)68(57.6%)0.535Nitrates103 (58%)67 (56.8%)0.853Warfarin63 (35.4%)31 (26.3%)0.099Clopedogril75 (42.1%)58 (49.2%)0.235Aldesterone antagonist88 (49.4%)50 (42.4%)0.233Digixon67 (37.6%)32 (27.1%)0.060Duration of stay8.71 ± 77.06 ± 50.020Mortality19 (10.7%)13(11.1%)0.740HFpEF65 (36.5%)45(38.1%)0.524Sepsis1 (0.6%)3(2.5%)0.254Pneumonia5 (2.81%)6 (5.1%)0.204AKI23 (13%)12 (10.2%)0.336CKD/ESRD7 (4%)3 (2.5%)0.291Resp. failure0(0%)4(3.4%)0.016liver failure1(0.6%)9(7.6%)0.000Tamponade1 (0.6%)3 (2.5%)0.254GIT bleeding1 (0.6%)3 (2.5%)0.148CCI167 (93%)112 (94%)0.692Previous MI54 (30.3%)17 (14.4%)0.003Previous CHF85 (47.8%)42 (35.6%)0.054PVD5 (2.8%)2 (1.7%)0.296CVA/TIA9 (5.1%)10 (8.5%)0.167Hemiplegia1 (0.6%)2 (1.7%)0.220COPD15 (8.4%)10 (8.5%)0.351VHD14 (7.8%)18(15.2%)0.020Peptic ulcer0 (0%)1(0.85%)0.163Cancer0 (0%)1 (0.85%)0.163Depression1 (0.6%)2 (1.7%)0.220Dementia6 (3.4%)3 (2.5%)0.328Metastasis1 (0.6%)3 (2.5%)0.148Endotracheal intubation27 (15.2%)15 (13%)0.553HIV1 (0.6%)1 (0.85%)0.336Cellulitis1 (0.6%)9 (7.6%)0.000PCI20 (11.2%)7 (6%)0.021CRT3 (1.68%)2 (1.69%)0.329Mechanical ventilation28 (15.7%)15 (22%)0.471CVP121 (68%)71 (60%)0.168CA4 (2.25%)5 (4.24%)0.329DC shock8 (4.5%)1 (0.85%)0.044Coma1 (0.6%)0 (0%)0.437Fever1 (0.6%)1 (0.85%)Hemoptysis0 (0.6%)1 (0.85%)Lanoxin toxicisty0 (0%)1 (0.85%)Mechanical ventilation28 (15.7%)15(21.7%)0.471Amiodarone17 (9.6%)7 (14.4%)0.200UFH62(34.8%)34(28.8%)0.279LMWH100(56.2%)79 (67%)0.064Lytic therapy45 (25.3%)32(27.1%)0.724ACEI/ARBS112(62.9%)78(66.1%)0.741Warfarin22 (12.4%)22(18.6%)0.137Beta-blockers61 (34.3%)45 (38%)0.794Survivors159 (89%)105 (88%)0.750*BMI* body mass index, *DM* diabetes mellitus, *HTN* hypertension, *STEMI* ST segment elevation myocardial infarction, *UA* unstable angina, *IE* infective endocarditis, *PE* pulmonary embolism, *PND* paroxysmal nocturnal dyspnea, *CHB* complete heart block, *Af* atrial flutter, *AF* atrial fibrillation, *CCI* Charlson comorbidity index, *PCI* percutaneous coronary intervention, *CA* coronary angiography, *CVA* cerebrovascular accident Table 2Clinical characteristics and co morbidities of females with and without HFNo HF, *N* = 277HF, *N* = 118*P* valueNo HF, *N* = 277HF, *N* = 118*P* valueClinical data and etiologyAssociated comorbiditiesAge49.8 ± 14.560.3 ± 10.50.000Sepsis/shock5 (1.8%)3 (2.5%)0.049BMI30.35 ± 3.131.6 ± 40.000Pneumonia5 (1.8%)6 (5.1%)0.025Obesity150 (54.5%)80 (67.8%)0.012AKI20 (7.22%)12 (10.17%)0.114DM125 (41.6%)45 (38.1%)0.199CKD/ESRD6 (2.2%)3 (2.5%)0.136HTN121 (61.2%)67 (56.8%)0.017Respir failure2 (0.72%)4 (3.4%)0.019Dyslipidemia86 (33.1%)47 (39.8%)0.091Liver failure1 (0.36%)9 (7.6%)0.000Smoking153 (67.4%)2 (1.7%)0.619Tamponade9 (3.25%)3 (2.5%)0.021Previous MI10 (3.6%)19 (16.1%)0.000GIT bleeding1 (0.36%)3 (2.5%)0.047Previous PCI10 (3.6%)12 (10.2%)0.004Previous MI6 (2.2%)17 (14.4%)0.000Previous CABG3 (1.1%)8 (6.78%)0.001Prior CHF3 (1.1%)42 (35.6%)0.000Valve surgery0 (0%)6 (5.1%)0.000PVD3 (1.1%)2 (1.7%)0.123Addiction3 (7.3%)0 (0%)0.256CVA/TIA5 (1.8%)10 (8.5%)0.001STEMI55 (20%)16 (14%)0.053Hemiplegia1 (0.36%)2 (1.7%)0.052UA/NSTEMI74 (26.7%)21 (8.5%)0.000COPD14 (5.1%)10 (8.5%)0.056Cardiogenic shock0 (0%)25 (21.2%)0.000DM/end organ damage7 (2.5%)8 (6.8%)0.017CHB32 (11.6%)1 (0.8%)0.000Mild liver dis5 (1.8%)1 (0.85%)0.111AF/Flutter25 (9%)22 (18.6%)0.007Severe liver dis2 (0.72%)1 (0.85%)0.139IE8 (3%)1 (0.8%)0.000peptic ulcer0 (0%)1 (0.85%)0.043PE79 (28.5%)3 (2.5%)0.000Cancer12 (4.33%)1 (0.85%)0.031Aortic dissection1 (0.4%)3 (2.5%)0.047Metastasis8 (2.88%)3 (2.5%)0.26HR (b/min)108.9 ± 38110 ± 370.758Dementia0 (0%)3 (2.5%)0.004SBP (mmHg)128.7 ± 29121.54 ± 370.03Autoimmu. D13 (4.7%)3 (2.5%)0.009DBP (mmHg)80.2 ± 1875.3 ± 20.50.01CCI277 (100%)112 (94.9%)0.000Hospital stay (days)7.14 ± 67.06 ± 50.892Mortality (%)14 (5.1%)13 (11.1%)0.041*BMI* body mass index, *DM* diabetes mellitus, *HTN* hypertension, *STEMI* ST segment elevation myocardial infarction, *UA* unstable angina, *IE* infective endocarditis, *PE* pulmonary embolism, *CHB* complete heart block, *Af* atrial flutter, *AF* atrial fibrillation, *PCI* percutaneous coronary intervention, *CA* coronary angiography, *CVA* cerebrovascular accident, *HR* heart rate, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *CCI* Charlson comorbidity index Table 3Clinical characterestics, co-morbidities and medications in HFrEF and HFpEF subgroupsHFrEF, *n* = 73HFpEF, *n* = 45*P* valueAge (years)66.9 ± 952.3 ± 110.0001Chest pain (CP)22 (30%)1 (2.22%)0.001Killip class I7 (9.6%)4 (9%)0.935 II4 (5.5%)2 (4.44%)0.915 III16 (22%)11 (24.44%)0.887 IV44 (60.3%)27 (60%)0.941Orthopnea50 (68.5%)30 (66.67%)0.932PND12 (16.4%)4 (9%)0.488Palpitations3 (4.12%)11 (24.44%)0.004Syncope1 (1.4%)0 (0%)0.692Cough dry3 (4.12%)5 (11.11%)0.142Productive cough19 (26%)11 (24.44%)0.339Edema26 (35.6%)12 (26.67%)0.256Previous MI13 (17.8%)6 (13.33%)0.500Previous PCI9 (12.3%)3(6.67%)0.380Previous CABG7 (9.6%)1(2.22%)0.190Valve surgery1 (1.4%)5(11.11%)0.035STEMI16 (21.9%)0 (0%)0.002STEMI16 (21.9%)0 (0%)0.002UA/NSTEMI8 (11%)13(28.9%)0.000CHB1 (1.34%)0 (0%)0.436AF/flutter10 (13.7%)12 (26.6%)0.039IE0 (0%)1 (2.2%)0.077PE1 (1.34%)2 (4.44%)0.303Aortic dissection1 (1.34%)2 (4.44%)0.303Hypertension4(5.5%)11(24.44%)0.000Prior HF20 ( 27%)8 (17.78%)0.000RHD0 (0%)4 (8.89%)0.000Pacemaker1 (1.4%)2 (4.44%)0.108ICD1 (1.4%)0 (0%)0.436CVP52 (71.2%)19 (42.2%)0.002Endotracheal intubation15 (20.5%)0 (0%)0.001Thazides22 (12.4%)8 (6.8%)0.119Loop diuretics109 (61%)68 (57.6%)0.535Nitrates103 (58%)67 (56.78%)0.853Warfarin63 (35.4%)31 (26.3%)0.099Clopedogril75 (42.1%)58 (49.2%)0.235Hospital stay7.88 ± 5.75.73 ± 3.40.02Sepsis1 (1.4%)2 (4.4%)0.303Pneumonia4 (5.5%)2 (4.44%)0.575Fever0 (0%)1 (2.22%)0.172Hemoptesis1 (1.4%)0 (0.85%)Lanoxin toxicisty0 (0%)0 (0%)1 (2.22%)1 (2.22%)CKD/ESRD3 (4.12%)0 (0%)0.236Respiratory failure2 (2.7%)2 (4.44%)0.511liver failure3 (4.12%)6 (13.3%)0.067Tamponade1 (1.4%)2 (4.44%)0.303GIT bleeding1 (1.4%)2 (4.44%)0.303CCI71 (97.3%)41 (91%)0.140Previous MI13 (17.8%)4 (4.44%)0.261AKI12 (16.4%)0 (0%)0.016PVD1 (1.4%)1 (2.22%)0.549CVA/TIA7 (9.6%)3 (6.7%)0.518Hemiplegia2 (2.7%)0 (0%)0.322COPD7 (9.6%)3 (6.67%)0.056Autoimmune8 (11%)0 (0%)0.046Mild liver diseases1 (1.4%)0 (0%)0.436peptic ulcer0 (0%)1 (2.22%)0.254Cancer1 (1.4%)0 (0%)0.436Metasis1 (1.4%)2 (4.4%)0.303Dementia1 (1.4%)2 (4.44%)0.336Rheumatic D1 (1.4%)2 (4.4%)0.303HIV0 (0%)1 (2.22%)0.254Cellulitis3 (4.12%)6 (13.%)0.067Depression0 (0%)2 (4.4%)0.108Mechanical ventilation14 (19.2%)1 (2.22%)0.007Pricardiocentesis0 (0%)1 (2.22%)0.201PCI7 (9.6%)0 (0%)0.032Coronary angiography5 (6.8%)0 (0%)0.073Amiodarone17 (9.6%)7 (14.4%)0.200Unfractunated heparin62 (34.8%)34(28.8%)0.279LMWH100 (56.2%)79 (67%)0.064Lytic therapy45 (25.3%)32 (27.1%)0.724Mortality12 (16.4%)1 (2.22%)0.01*BMI* body mass index, *DM* diabetes mellitus, *HTN* hypertension, *STEMI* ST segment elevation myocardial infarction, *UA* unstable angina, *IE* infective endocarditis, *PE* pulmonary embolism, *CHB* complete heart block, *Af* atrial flutter, *AF* atrial fibrillation, *PCI* percutaneous coronary intervention, *CA* coronary angiography, *CVA* cerebrovascular accident, *HR* heart rate, *SBP* systolic blood pressure, *DBP* diastolic blood pressure

Comparison between women and men with HF {#Sec7}
----------------------------------------

Women with HF were older in age, more obese, and less symptomatic than men. Women had higher incidence of associated comorbidities like liver failure, respiratory failure, and cellulitis. On the contrary, the prevalence of smoking, addiction, and previous MI and PCI were lower in women than in men. Women are less liable to be repeatedly admitted to the hospital for HF and less likely to have ischemic heart disease as underling etiology of HF. However, valvular heart diseases (VHD), atrial fibrillation (AF), and cardiomyopathies were more likely to be the etiologies of their HF (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Women characteristics of HFrEF and HFpEF

Accordingly, with the lower prevalence of coronary heart disease, women were less likely to undergo percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Meanwhile, women treated with implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) and cardiac pacemakers at similar frequencies as men with HF.

Compared to men, women with HF had more normal ECG: 36 (30.5%) versus 36 (20.2%) *P* \< 0.01, more prevalence of left anterior hemiblock (LAH) 5 (4.2%) versus 2 (1.1%) *P* \< 0.02, AF 30 (25.4%) versus 30 (16%) *P* \< 0.04, and less likely to have LBBB 15 (12.7%) versus 60 (33.7%), *P* \< 0.00001. Regarding echocardiographic data, women had higher EF% 47 ± 13 versus 40 ± 13, *P* \< 0.05 and smaller LA size 18.18 ± 18 versus 22.69 ± 19, *P* \< 0.04; nevertheless, there was no considerable difference between women and men in grades of diastolic dysfunction, severity of mitral regurg, RWMA or E/e\' (*P* = NS), or routine laboratory workup.

There was no significant difference in medications of invasive procedures like central venous pressure (CVP), endotracheal intubation, pacemakers, or ventilation prescribed during CCU admission between women and men.

Women with HF showed shorter stay in CCU compared to men. The mortality risk during hospitalization did not differ by gender (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Mortality risk in study subgroups

Comparison between women with and without HF {#Sec8}
--------------------------------------------

Comparing the 118 females with HF to 277 patients without HF (Table [2](#Tab2){ref-type="table"}), HF females were older, more obese with higher BMI, had prevalent prior MI, with more PCI, CABG, and valve surgery. Females with HF had a higher prevalence of STEMI, NSTEMI/UA, pulmonary embolism (PE), infective endocarditis (IE), and aortic dissection and higher incidence of significant arrhythmias like AF and CHB. More hemodynamic compromise is recorded in HF female's subgroup including higher heart rate and more hypotension. Additionally, women with HF had more frequent associated comorbidities, hepatic diseases, GIT bleeding, CVD, dementia, respiratory failure, peptic ulcer, and pneumonia. However, non-HF women had higher prevalence of cancer and autoimmune diseases.

On ECG, women with HF had higher prevalence of voltage criteria 14 (11.9%) versus 1 (0.44%), *P* \< 0.0001, AF \[30(25%) versus 11(4%)\] *P* \< 0.0001 pathologic Q wave 36 (30.5%) versus 62 (22.4%) *P* \< 0.0001 compared to non-HF subgroup.

Regarding laboratory workup, women with HF had higher LDL level (154.15 ± 38 versus 140.88 ± 33 mg/dl, *P* \< 0.01), FBS (209.66 ± 145 versus 149.76 ± 108 mg/dl, *P* \< 0.001) higher A1c level 9.03 ± 2 versus 7.83 ± 3, *P* \< 0.001, higher creatinine level (2.24 ± 3.2 versus 1.41 ± 1 mg/dl), ALT (65.7 ± 68 versus 42.41 ± 34 u, P \< 0.0001) and higher INR ratio (1.54 ± 1 versus 1.21 ± 1, mg/dl, *P* \< 0.001), lower hemoglobin (10.96 ± 3 versus12.00 ± 1, gm/dl *P* \< 0.0001) and albumin (3.86 ± 1 versus 4.03 ± 1 mg/dl, *P* \< 0.001.

The higher risk profile of women with HF is associated with increased mortality risk despite similar duration of hospital stay.

HFrEF and HFpEF in women {#Sec9}
------------------------

Unexpectedly, HFrEF was the commonest type of HF 73 (61.9%) versus HFpEF 45 (38.1%) in females (*P* \< 0.001); the averaged value of EF was 33.88% in patients with reduced EF, while it was within the normal range for patients with preserved EF (61.4%) (Table [4](#Tab4){ref-type="table"}). Comparing patients with reduced EF, to patients with preserved EF, they were significantly younger, had prevalent hypertension, more UA/NSTEMI, less STEMI and CABG, and less valve surgery. The causes of HF were ACS in a larger percentage of patients with reduced EF, where hypertensive heart disease and valvular HD were more common in those with preserved EF. Patients with reduced EF were also more likely to have frequent admission to hospital with CHF and more comorbidities like acute kidney injury (AKI) and COPD, while no difference in medications prescribed by CCU physicians between the two types. In contrast, mechanical ventilation, pacemakers, and CVP were higher in HFrEF. Clopidogrel, proton pump inhibitors (PPIH) and aspirin (ASA) were more commonly prescribed to HFrEF while calcium channel blockers (CCB) were more frequently prescribed to HFpEF (Table [5](#Tab5){ref-type="table"}). Table 4ECHO findings in female HF typesMean*P* valueLVEDd (mm)HF-REF39.07 ± 250.004HF-PEF17.53 ± 22LVESd (mm)HFrEF23.84 ± 210.025HFpEF15.05 ± 20IVS (mm)HFrEF5.42 ± 50.021HFpEF3.40 ± 4PWT (mm)HFrEF5.36 ± 50.018HFpEF3.30 ± 4EF%HFrEF33.88 ± 120.001HFpEF61.96 ± 12LA (mm)HFrEF21.50 ± 190.012HFpEF12.87 ± 16AO (mm)HFrEF28.26 ± 16.50.015HFpEF10.76 ± 15TAPSE (mm)HFrEF6.84 ± 5.10.235HFpEF8.65 ± 4EPASP (mm)HFrEF42.26 ± 130.503HFpEF40.12 ± 20E/A waveHFrEF1.47 ± 10.409HFpEF1.67 ± 1E/e\' waveHFrEF18.31 ± 9.50.023HFpEF23.62 ± 12RWMAHFrEF62 (85%)0.002HFpEF27 (60%)*HFrEF* heart failure with reduced ejection fraction, *HFpEF* heart failure with preserved ejection fraction, *LVEDd* left ventricular end diastolic diameter, *LVESd* left ventricular end systolic diameter, *IVS* interventricular thickness, *PWT* posterior wall thickness, *EF%* ejection fraction, *LA* left atrium, *Ao* aortic root diameter, *TAPSE* tricuspid annular plane systolic excursion, *EPASP* estimated pulmonary artery systolic pressure, *E?A* mitral flow early diastolic velocity, *A* mitral inflow atrial diastolic velocity, *E/e* mitral flow early diastolic velocityto early diastolic mitral annular velocity, *RWMA* regional wall motion abnormalities Table 5Medications in women with HFrEF and HFpEF subgroupsHFrEF, *n* = 73HFpEF, *n* = 45*P* valueThazides5 (6.85%)3 (6.7%)0.969Loop diuretics40 (54.8%)28 (62.22%)0.428Nitrates39 (53.4%)28 (62.22%)0.349Warfarin17 (23.3%)14 (31.11%)0.348Clopidogril41 (56.2%)17 (37.8%)0.052CCB2 (2.74%)6 (13.33%)0.026Amiodarone10 (13.7%)7 (15.6%)0.780Unfractunated heparin19 (26.02%)15 (33.33%)0.395LMWH52 (71.23%)27 (60%)0.208Lytic therapy24 (32.88%)8 (17.8%)0.073Aldosterone antagonist32 (43.8%)18 (40%)0.682Digixon19 (26.03%)13 (28.9%)0.734PPIH blockers55 (75.34%)42 (93.3%)0.013Warfarin A10 (13.7%)12 (26.7%)0.079ASA60 (82.2%)28 (62.22%)0.016Beta-blockers27 (37%)18 (40%)0.743ACEI38 (52.1%)22 (49%)0.738ARBs8 (11%)10 (22.22%)0.098Statin58 (79.5%)32 (71.1%)0.301*CCB* calcium channel blockers, *LMWH* low molecular weight heparin, *ASA* acetyl salsylic acid, *ACEI* angiotensin converting enzyme inhibitor, *ARBS* angiotensin receptor blockers

Regarding ECG changes, women with HFpEF had higher prevalence of voltage criteria, 13 (28.9%) versus 1 (0.4%) in HFrEF, *P* \< .00001, but lower frequency of pathologic Q and ischemic changes, 14 (31%) versus 32 (43.8%) in HFrEF, *P* \< 0.0001.

Patients with HFpEF illustrated shorter duration of hospital stay compared with those with HFrEF. However, HFrEF showed higher risk of mortality compared to HFpEF. Mortality was significantly higher in HFrEF 12% versus 1% in HF with HFpEF.

Discussion {#Sec10}
==========

In the current study, the main findings are that substantial gender differences exist among Egyptian HF patients; women with HF are older, more obese, less smoker, and have more comorbidities, and HFrEF is the commonest type. Valvular heart diseases and cardiomyopathies are commonest etiology of HF. Female HF patients have similar survival during hospital course compared with men with HF.

Gender difference in clinical characteristics in CCU HF patients {#Sec11}
----------------------------------------------------------------

The present study demonstrated gender differences in patients' clinical characteristics, comorbidities, and short-term outcome who were admitted to CCU. Female patients were characterized by older age, higher LVEF, lower prevalence of ACS, larger incidence of valvular heart disease, and cardiomyopathies in our study which is consistent with previous reports \[[@CR8], [@CR9]\].

The clinical manifestations of HF appeared to be less severe in women compared with men, and women had lower NYHA functional class but similar laboratory workup despite the higher and preserved LVEF%. Treatment according to latest guidelines, however, was equally or even similar to that given to women compared with men. This is in contrast to previous reports from Japanese registry \[[@CR7]\].

Women in CCU HF patients {#Sec12}
------------------------

While previous studies of HFpEF reported that the female sex is dominant in patients with HFpEF \[[@CR10]\], in the current study, the proportion of female to male in HFpEF was almost the same. The proportions of the females were 42% in the Japanese Diastolic Heart Failure Study (JDHF) \[[@CR11]\] and 45% in the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) \[[@CR12]\], both studies enrolled Japanese patients. However, in the current registry, the proportion of HFpEF in female HF patients was similar to men: 73 (61.9%) had HFrEF versus 113 (63.5%) in men, *P* = 0.345 while 45(38.1%) had HFpEF in women versus 65 (36.5%) in men, *P* = 0.378.

The clinical characteristics of the study population were almost comparable to those of the ADHERE and OPTIMIZE-HF \[[@CR6], [@CR7]\]. HF patients with reduced EF were older, more obese, and more likely to have ACS. They were less likely to have a hypertension or valvular HD.

Higher prevalence of HFrEF in female patients most likely reflects the impact of age on cardiac structure and the high prevalence of coronary artery disease in this group of HF patients. HFpEF female patients had higher prevalence of hypertension and atrial fibrillation, which may possibly be a consequence as well as a causative factor for clinical presentation of such type of HF.

Additionally, respiratory failure, hepatic failure, cellulites, anemia, and hypo-albuminemia are the common comorbidities compared to men. Anemia is a strong predictor of mortality and morbidity in HF patients \[[@CR5], [@CR9]\], also appeared to be highly prevalent in our study, might be explained by renal dysfunction, older age, and more obesity that seems to explain the large discrepancy.

Basic HF therapy in the form of diuretics, renin-angiotensin system (RAS) inhibition, ACE-inhibitors, or angiotensin receptor blockers in 66% and aldosterone antagonist in 42% were similarly utilized in both women and men. These percentages are noticeably higher compared to Asian AHF registry \[[@CR10]\] where ACEI/ARBS used in only 37% and spironolactone in 34%. Actually, the worse renal function in Asian registry (creatinine clearance 69 ml/min in this young population) could be an explanation. In accordance to our registry, the lower use of beta-blockers in 34% and 24% in Asian registry is considered and might reflect the concern of worsening HF in patients with already advanced syndrome. Digoxin and nitrates are easily available drugs traditionally but employed modestly in women with HF, it may reflect slower adoption of contemporary HF management and/or lower cost of these drugs \[[@CR13]\].

Gender difference in short-term prognosis {#Sec13}
-----------------------------------------

One of the main findings of the present study is the similar mortality rate during CCU admission in both gender despite the difference of HF etiology, the clinical presentation, patients risk profile, and comorbidities. Our findings are confirmed by the Sakata et al. \[[@CR8]\] in their report from the CHART-2 study, and they examined the gender difference in long-term outcome in 4736 consecutive CHF patients and found that the incidence of mortality and other events in women and men with stage C/D HF experienced 52.4 and 47.3 deaths per 1000 person-years (*P* = 0.225) and 58.3 and 51.3 cases of HF requiring admission per 1000 person-years (*P* = 0.189), respectively. They concluded that there were no gender differences in all-cause death and HF requiring admission, although the incidences of both events are much higher than those of AMI or stroke \[[@CR12]\]

Limitations {#Sec14}
===========

The present study had following limitations. First, this was a single-center study involving a relatively small number of HF patients that included both gender and both types of HF (HFrEF and HFpEF) patients. Second, our registry population was limited to patients who were admitted to the CCU; HF patients who were admitted to general wards were excluded from this study. Third, this study was designed for short term outcome and had a relatively no follow-up period like those in previous reports.

Conclusion {#Sec15}
==========

In conclusion, although female patients had different clinical characteristics and underlying etiologies of HF which is varied from male gender, their short-term outcome and hospital mortality are similar. HF with reduced ejection fraction was present in a considerable proportion of hospitalized female patients admitted to CCU in unselected critically ill stage and associated with higher mortality risk compared to HFpEF. Given the higher risk of adverse clinical events and the lack of a satisfactory proof to guide the treatment, clinical trials are critically required to identify the effective preventive strategies for women with HF.

CCU

:   Cardiac care unit

HF

:   Heart failure

HFpEF

:   Heart failure with preserved ejection fraction

HFrEF

:   Heart failure with reduced ejection fraction

ACS

:   Acute coronary syndrome
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